Back

Teva Pharma Industries Ltd ADR

Ticker: TEVA ISIN: US8816242098
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Trading above 200-day average Near 52-week high
Market cap
$20.72B
Forward P/E
6.96
Profit margin
-0.94%
Revenue growth QoQ
0.30%
Beta
0.62
$37.34 1.44%
Price as of 2026-08-21 · NYSE

Performance by timeframe

Rolling returns
1 Month +21.19%
6 Months +10.12%
1 Year +106.07%
5 Years +31.60% p.a.+294.30%
10 Years -2.70% p.a.-23.92%
Since inception +4.17% p.a.+177.74%
Calendar year returns
YTD +19.64%
2025 +41.61%
2024 +111.11%
2023 +14.47%
2022 +13.86%
2021 -16.99%

Key stats

Market cap
20.72B
Beta
0.62
52-week range
12.47 - 22.80
50-day MA
16.72
200-day MA
17.21
Section 1

Business overview

Company profile data from fundamentals.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Country Israel
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -2.42%
ROA 5.37%
Profit margin -0.94%
Operating margin 21.41%
PEG ratio 1.29
Revenue/share TTM 14.61
Revenue TTM 16.63B
EBITDA 4.52B
Gross profit TTM 8.25B
Beta 0.62

Valuation

Trailing P/E 0.00
Forward P/E 6.96
P/B 3.03
P/S 1.25
EV/EBITDA 19.12
EV/Revenue 2.18

ESG Scores

Total ESG 58.8
Environment 77.0
Social 47.2
Governance 65.3
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 2.58
Quarterly earnings growth 40.00%
Revenue TTM 16.63B
Reported quarters 120
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Ex-dividend date 2017-11-27
Split factor 2:1
Last split date 2004-07-01
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $23.56
Analyst rating 4.4546

Ownership & short interest

Shares outstanding 1.15B
Shares float 1.14B
Institutional ownership 66.22%
Insider ownership 0.20%
Short ratio 4.27
Short % of float 4.37%

Details

Instrument metadata and source update timestamps.

Symbol TEVA
Name Teva Pharma Industries Ltd ADR
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US8816242098
Country USA
Code + exchange TEVA.NYSE
Fundamentals updated 2025-08-19

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.